In a post-earnings research note titled "The Time to Buy is Now," Citi analyst Yigal Nochomovitz raised his price target for Portola Pharmaceuticals to $51 from $50 and keeps a Buy rating on the shares. The analyst continues to believe Andexxa can be a ~$250M product in 2020 and ~$550M by 2022. Getting to half a billion in sales would require one use per month per hospital, assuming "only" ~1500 active hospitals, which is "very achievable," Nochomovitz tells investors in a research note. This means Portola's fair value is ~$50 per share, not the market view of $27 per share, says the analyst.